Previous 10 | Next 10 |
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announc...
LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announce...
ProQR (NASDAQ: PRQR ): Q2 GAAP EPS of -€0.30. More news on: ProQR Therapeutics N.V., Earnings news and commentary, Healthcare stocks news, Read more ...
LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported...
ProQR Therapeutics (NASDAQ: PRQR ) announces that its sepofarsen (QR-110) drug candidate for the treatment of Leber’s congenital amaurosis 10 (LCA10), was granted access to the PRIority MEdicines (PRIME) program by the European Medicines Agency (EMA). More news on: ProQR Therapeut...
Access based on positive interim analysis of clinical data as well as preclinical data to date PRIME designation provides a pathway for frequent and early interactions with the EMA aimed at supporting accelerated evaluation and approval ProQR believes that the EU will represent...
Gainers : Tower International (NYSE: TOWR ) +69% . Camber Energy (NYSEMKT: CEI ) +50% . HOOKIPA Pharma (NASDAQ: HOOK ) +28% . Milacron Holdings (NYSE: MCRN ) +25% . VivoPower International PLC (NASDAQ: VVPR ) +21% . ProQR Therapeutics N.V. (NASDAQ: PRQR ) +21% . Oasmi...
ProQR Therapeutics N.V. ( PRQR +12.9% ) is up on slightly higher volume ahead of a presentation on candidate QR-421a in Usher syndrome tomorrow at the Annual Usher Connections Conference in Philadelphia. More news on: ProQR Therapeutics N.V., Healthcare stocks news, Stocks on the move,...
LEIDEN, Netherlands and CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced an upcoming presen...
LEIDEN, Netherlands and CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced an upcoming presen...
News, Short Squeeze, Breakout and More Instantly...
ProQR Therapeutics N.V. Company Name:
PRQR Stock Symbol:
NASDAQ Market:
ProQR Therapeutics N.V. Website:
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27 th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight data Martin Maier, PhD nominated to Board with Annual General Meeting scheduled f...
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides Preclinical proof of concept for the Company’s AX-0810 pr...
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the An...